Navigation Links
Announcement - Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System
Date:2/17/2011

MOUNTAIN VIEW, Calif., Feb. 17, 2011 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the Tet-Express Inducible Expression System, which provides the quickest and simplest Tet-inducible expression technology yet. At the heart of this new system is a cell membrane-permeable version of Clontech's Tet-Off® Advanced transcriptional activator protein (the Tet-Express transactivator) that can enter cells directly, i.e., without transfection. The Tet-Express system eliminates the requirement for a double-stable cell line expressing both the gene of interest and the tetracycline transactivator. Instead, only the gene of interest is cloned into the cells; then when gene expression is required, simply add the self-transducing Tet-Express protein directly to the cells in order to turn on the gene of interest. Since the Tet-Express protein binds and activates expression in the absence of tetracyclines, doxycycline is not required for gene activation, further simplifying the system. Clontech has filed for patent protection for the Tet-Express system.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in developing technologies for gene delivery and expression. We are pleased to continue and extend this history by adding the Tet-Express Inducible Expression System to our portfolio of Tet System Products, which are the gold standard for regulated gene expression."

For maximal expression and minimal background, the Tet-Express Inducible Expression System contains Clontech's latest and tightest Tet System promoter, TRE3G, which is found in Clontech's Tet-On® 3G Expression Systems (developed and marketed under a license from TET Systems GmbH and Co. KG). The Tet-Express System makes tetracycline-controlled transcription a rapid process for all cell types, and is particularly advantageous for cell types that are not amenable to sequential rounds of clonal selection. In addition, the Tet-Express System provides a novel way to screen clones for inducible expression of the gene of interest before moving on to make stable lines, by allowing the researcher to test induction in the clones simply by adding the Tet-Express transactivator to the culture medium.

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™, Titanium®, and Advantage® enzymes); RT enzymes and SMART™ library construction kits; the innovative In-Fusion® cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.

About TET Systems.

TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 36 granted patents and 14 patent applications. TET Systems markets licenses to the Tet Technology. To date, more than 160 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.


'/>"/>
SOURCE Clontech Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
2. VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement
3. Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2011 Results
4. Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2010 Financial Results Announcement
5. VirtualScopics Schedules Third Quarter 2010 Earnings Announcement
6. Lilly Confirms Date and Conference Call for Third-Quarter 2010 Financial Results Announcement
7. Perrigo Confirms Filing for Omeprazole/Sodium Bicarbonate and Announcement of Patent Infringement Lawsuit by Schering-Plough Healthcare Products
8. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
9. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
10. Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
11. Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced ... Market Prospects: Addressing Production Complexities Through Risk Management and ... ... Pipeline and Market Prospects: Overcoming Production Complexities Through Risk ... of the current trends in the global biosimilars market, ...
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... Brian Emmer brings ... of Sales and Business Development at OAKWORKS, Inc. Mr. Emmer is responsible ... and strategic planning for the company. Recognized industry-wide as a healthcare innovator, ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
(Date:4/21/2017)... ... ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , has found the ... located on the forehead usually attributed to a facial fracture. Their appearance is not ... has discovered an approach that is minimally invasive. He is an expert at this ...
(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a global leader ... and B-7569 vinyl label materials received certification for the BS5609 British ... to remain intact and legible, for use on chemical drums shipped by sea. ...
Breaking Medicine News(10 mins):